CEP120

Across TCGA pan-cancer cohorts, CEP120 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CEP120 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher CEP120 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP120 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

PRAD, UCEC, and LUSC are the cancer types where CEP120 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	OS	Median	All	0.491	0.893	<.001	8	view →
UCEC	DFS	Median	All	0.955	0.827	.020	8	view →
LUSC	DFS	Median	All	1.000	0.370	.039	4	view →
LIHC	OS	Median	All	0.192	0.514	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CEP120–PRAD (OS)

Open the PRAD breakdown →